kwic
treatment
treatment
right
off
ON
408
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for treatment out of >500 occurrences
677804 occurrences (No.8 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to treatment]
677804 occurrences (No.8 in the rank) during 5 years in the PubMed. [cache]
| 408) Rationale for selecting a specific regimen and for treatment eligibility criteria were poorly documented across studies. |
| PMID:34072615 DOI:10.3390/curroncol28030191 |
| 2021 Current oncology (Toronto, Ont.) |
| * Interventions and Outcomes for Neoadjuvant Treatment of T4 Colon Cancer: A Scoping Review. |
| - While adjuvant treatment of colon cancers that penetrate the serosa (T4) have been well-established, neoadjuvant strategies have yet to be formally evaluated. Our objective was to perform a scoping review of eligibility criteria, treatment regimens, and primary outcomes for neoadjuvant approaches to T4 colon cancer. A librarian-led, systematic search of MEDLINE, Embase, Cochrane Library, Web of Science, and CINAHL up to 11 February 2020 was performed. Primary research evaluating neoadjuvant treatment in T4 colon cancer were included. Screening and data abstraction were performed in duplicate; analyses were descriptive or thematic. A total of twenty studies were included, most of which were single-arm, single-center, and retrospective. The primary objectives of the literature to date has been to evaluate treatment feasibility, tumor response, disease-free survival, and overall survival in healthy patients. Conventional XELOX and FOLFOX chemotherapy were the most commonly administered interventions. Rationale for selecting a specific regimen and for treatment eligibility criteria were poorly documented across studies. The current literature on neoadjuvant strategies for T4 colon cancer is overrepresented by single-center, retrospective studies that evaluate treatment feasibility and efficacy in healthy patients. Future studies should prioritize evaluating clear selection criteria and rationale for specific neoadjuvant strategies. Validation of outcomes in multi-center, randomized trials for XELOX and FOLFOX have the most to contribute to the growing evidence for this poorly managed disease. |
[
right
kwic]
(1)68  of |
(13)7 planning |
(25)3 outcome |
(37)2 efficacy |
| (2)50 *null* | (14)6 to |
(26)3 protocols |
(38)2 goals |
| (3)29 and |
(15)4 approaches |
(27)3 that |
(39)2 group |
| (4)23 for |
(16)4 methods |
(28)2 a |
(40)2 groups |
| (5)22 with |
(17)4 option |
(29)2 as |
(41)2 may |
| (6)15 options |
(18)4 options, |
(30)2 at |
(42)2 ranks |
| (7)13 in |
(19)4 ranking |
(31)2 being |
(43)2 reduced |
| (8)9 effect |
(20)4 regimens |
(32)2 compared |
(44)2 resistance |
| (9)9 effects |
(21)4 strategies |
(33)2 decisions, |
(45)2 screening, |
| (10)8 is |
(22)3 adherence |
(34)2 development |
(46)2 through |
| (11)8 on |
(23)3 approach |
(35)2 did |
(47)2 were |
| (12)7 outcomes |
(24)3 or |
(36)2 dose |
add keyword
--- WordNet output for treatment ---